Cabotegravir

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319641

CAS#: 1051375-10-0

Description: Cabotegravir, also known as S/GSK1265744 or GSK744, is potent HIV integrase inhibitor under development for the treatment of HIV infection. Cabotegravir has a carbamoyl pyridone structure similar to dolutegravir.


Price and Availability

Size
Price

10mg
Not available
100mg
Not available
1g
Ask price
Size
Price

25mg
Not available
200mg
Not available
2g
Ask price
Size
Price

50mg
Not available
500mg
Not available
5g
Ask price

Cabotegravir, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 319641
Name: Cabotegravir
CAS#: 1051375-10-0
Chemical Formula: C19H17F2N3O5
Exact Mass: 405.1136
Molecular Weight: 405.3578
Elemental Analysis: C, 56.30; H, 4.23; F, 9.37; N, 10.37; O, 19.73


Synonym: S/GSK1265744; S/GSK 1265744; S/GSK-1265744; GSK744; GSK-744; GSK 744; Cabotegravir.

IUPAC/Chemical Name: (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide

InChi Key: WCWSTNLSLKSJPK-LKFCYVNXSA-N

InChi Code: InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1

SMILES Code: C[C@H]1CO[C@H]2N1C(C3=C(O)C(C(C(NCC4=C(F)C=C(F)C=C4)=O)=CN3C2)=O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Gulick RM. Choosing Initial Antiretroviral Therapy: Current Recommendations for Initial Therapy and Newer or Investigational Agents. Top Antivir Med. 2015 Oct-Nov;23(4):128-31. PubMed PMID: 26713502.

2: Srinivas NR. Interspecies scaling of excretory amounts using allometry - retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion. Xenobiotica. 2015 Dec 29:1-9. [Epub ahead of print] PubMed PMID: 26711252.

3: Landovitz RJ, Kofron R, McCauley M. The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr Opin HIV AIDS. 2016 Jan;11(1):122-8. doi: 10.1097/COH.0000000000000219. PubMed PMID: 26633643.

4: Reese MJ, Bowers GD, Humphreys JE, Gould EP, Ford SL, Webster LO, Polli JW. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12. [Epub ahead of print] PubMed PMID: 26340566.

5: Margolis DA, Brinson CC, Smith GH, de Vente J, Hagins DP, Eron JJ, Griffith SK, St Clair MH, Stevens MC, Williams PE, Ford SL, Stancil BS, Bomar MM, Hudson KJ, Smith KY, Spreen WR; LAI116482 Study Team. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015 Oct;15(10):1145-55. doi: 10.1016/S1473-3099(15)00152-8. Epub 2015 Jul 19. PubMed PMID: 26201299.

6: Bowers GD, Culp A, Reese MJ, Tabolt G, Moss L, Piscitelli S, Huynh P, Wagner D, Ford SL, Gould EP, Pan R, Lou Y, Margolis DA, Spreen WR. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016 Feb;46(2):147-62. doi: 10.3109/00498254.2015.1060372. Epub 2015 Jul 1. PubMed PMID: 26134155.

7: Andrews CD, Heneine W. Cabotegravir long-acting for HIV-1 prevention. Curr Opin HIV AIDS. 2015 Jul;10(4):258-63. doi: 10.1097/COH.0000000000000161. PubMed PMID: 26049951.

8: Margolis DA, Boffito M. Long-acting antiviral agents for HIV treatment. Curr Opin HIV AIDS. 2015 Jul;10(4):246-52. doi: 10.1097/COH.0000000000000169. PubMed PMID: 26049949.

9: Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015 Jul;10(4):239-45. doi: 10.1097/COH.0000000000000168. PubMed PMID: 26049948.

10: Williams PE, Crauwels HM, Basstanie ED. Formulation and pharmacology of long-acting rilpivirine. Curr Opin HIV AIDS. 2015 Jul;10(4):233-8. doi: 10.1097/COH.0000000000000164. PubMed PMID: 26049947.

11: Gulick R. HIV treatment 2020: what will it look like? J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19528. doi: 10.7448/IAS.17.4.19528. eCollection 2014. PubMed PMID: 25394037; PubMed Central PMCID: PMC4224796.